Sign in

VCNX on OTC

VACCINEX, INC.

In its 2025 annual report the company says: “We are a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. We are focused on developing pepinemab for the treatment of Alzheimer’s disease, or AD and as our resources allow, also developing pepinemab for head and neck cancer, and pancreatic cancer.”3 It is headquartered in Rochester, New York.1 Its shares trade on OTC under the symbol VCNX.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with PMGC Holdings Inc., Ernexa Therapeutics Inc. or NovaBridge Biosciences, or pick any stock.

  • TickerVCNX on OTC1
  • IndustryPharmaceutical Preparations1
  • HeadquartersRochester, New York1
  • Incorporated inDE2
  • Business address1895 Mount Hope Ave, Rochester, Ny 146202
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. We believe we are the leader in the field of semaphorin 4D, or SEMA4D, biology and that we are the only company targeting SEMA4D as a potential treatment for neurodegenerative diseases, cancer, and autoimmune disorders. SEMA4D is an extracellular signaling molecule that regulates the activity of immune and inflammatory cells at sites of injury, cancer, or infection. We have used our SEMA4D antibody platform and our extensive knowledge of SEMA4D biology to develop our lead product candidate, pepinemab, an antibody that we believe utilizes novel mechanisms of action. We are focused on developing pepinemab for the treatment of Alzheimer’s di…3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-3117.3%Operating margin4
-3100.5%Net margin4
5.4%Revenue growth, 20244
-$16.2MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Research and development100¢$12.5M
  • Interest0¢$2.0K

Out of $601.0K in revenue.4 The company lost money this year.

Financial statements

Revenue567894$601.0K in 2024−17% since 2018
0$250.0K$500.0K$750.0K$1.0M2018: $724.0K$724.0K20182019: $523.0K$523.0K2019−28%2020: $625.0K$625.0K2020+20%2021: $900.0K$900.0K2021+44%2022: $275.0K$275.0K2022−69%2023: $570.0K$570.0K2023+107%2024: $601.0K$601.0K2024+5%
Operating income567894-$18.7M in 2024−31% since 2018
-$40.0M-$30.0M-$20.0M-$10.0M02018: -$27.3M-$27.3M20182019: -$32.0M-$32.0M2019+17%2020: -$28.3M-$28.3M2020−12%2021: -$22.5M-$22.5M2021−21%2022: -$19.9M-$19.9M2022−11%2023: -$22.9M-$22.9M2023+15%2024: -$18.7M-$18.7M2024−18%
Net income56794-$18.6M in 2024−37% since 2018
-$40.0M-$30.0M-$20.0M-$10.0M02018: -$29.5M-$29.5M20182019: -$31.9M-$31.9M2019+8%2020: -$28.9M-$28.9M2020−9%2021: -$22.4M-$22.4M2021−22%2022: -$19.8M-$19.8M2022−11%2023: -$20.3M-$20.3M2023+2%2024: -$18.6M-$18.6M2024−8%
Fiscal year2018201920202021202220232024
Revenue$724.0K5$523.0K6$625.0K7$900.0K8$275.0K9$570.0K4$601.0K4
Cost of revenue$1.0M5$199.0K6$2.0K7
Research and development$22.4M5$25.7M6$21.5M7$17.2M8$14.0M9$16.6M4$12.5M4
Operating expenses$23.4M8$20.2M9$23.5M4$19.3M4
Operating income-$27.3M5-$32.0M6-$28.3M7-$22.5M8-$19.9M9-$22.9M4-$18.7M4
Interest$392.0K5$489.0K7$809.0K8$2.0K9$1.0K4$2.0K4
Income before tax-$22.4M8-$19.8M9-$20.3M4-$18.6M4
Income tax$05$06$07$08$09$04$04
Net income-$29.5M5-$31.9M6-$28.9M7-$22.4M7-$19.8M9-$20.3M4-$18.6M4
Earnings per share-$0.788-$98.059-$43.684-$8.884
Earnings per share (diluted)-$0.788-$98.059-$43.684-$8.884
Shares (weighted, basic)28.8M shares8202.1K shares9463.7K shares42.1M shares4
Shares (weighted, diluted)28.8M shares8202.1K shares9463.7K shares42.1M shares4

Compare VACCINEX, INC. with another company

Corporate structure

VACCINEX, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of VACCINEX, INC.

  • ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on VACCINEX, INC., latest Feb 14, 2025 (2 filings since Nov 14, 2024)
  • Maurice Zauderer Filed SC 13D/A on VACCINEX, INC., latest Nov 18, 2024 (7 filings since Feb 10, 2022)
  • FCMI Parent Co. Filed SC 13D/A on VACCINEX, INC., latest Sep 20, 2024 (9 filings since Feb 14, 2022)
  • Point72 Asset Management, L.P. Filed SC 13G on VACCINEX, INC., latest Feb 9, 2024
  • Orin Hirschman Filed SC 13G/A on VACCINEX, INC., latest Feb 7, 2024 (2 filings since Oct 11, 2023)
  • VACCINEX, INC. Rochester, New York

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What VACCINEX, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$7.2M4 Dec 31, 2024$7.2M4 Dec 31, 2023+0.3%
Accumulated depreciation$7.2M4 Dec 31, 2024$7.1M4 Dec 31, 2023+1.3%
Property and equipment, net$65.0K4 Dec 31, 2024$136.0K4 Dec 31, 2023−52.2%
Operating-lease assets (leased space)$04 Dec 31, 2024$146.0K4 Dec 31, 2023−100.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1.1M4 Dec 31, 2024$1.5M4 Dec 31, 2023−27.9%

Properties, in its own words

Our principal executive office is located in Rochester, New York, and consists of approximately 31,180 square feet of leased office and laboratory space for our one operating segment. We believe that our properties are in good condition, are well maintained and are generally suitable and adequate to carry on our business in its current form.

Item 2 of the 10-K filed Apr 15, 2025.3

Leadership

Who has led VACCINEX, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Maurice Zauderer2018–2024

President

  1. Maurice Zauderer2018–2024

Chief financial officer

  1. Scott E. Royer2018–2023
  2. Jill Sanchez2024

Chief operating officer

  1. Raymond E. Watkins2018–2020
20202025
Board members and other officers (12)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerElizabeth S. Evans named Apr 12, 2024 to Sep 27, 202428
  • Executive OfficerErnest S. Smith Ph.D. named Apr 12, 2024 to Sep 27, 202428
  • Director, Executive OfficerMaurice S. Zauderer, Ph.D. named Apr 12, 2024 to Sep 27, 202428
  • DirectorBala S. Manian Ph.D. named Apr 12, 2024 to Sep 27, 202428
  • DirectorGerald E. Van Strydonck named Apr 12, 2024 to Sep 27, 202428

Former names

  • VACCINEX INCNov 12, 2002 to May 9, 20052

Timeline

  1. Mar 19, 20258-K Executive or director change29
  2. Mar 7, 20258-K Listing notice or transfer; Regulation FD disclosure30
  3. Dec 17, 20248-K Listing notice or transfer; Other events31
  4. Nov 14, 20248-K Entered a material agreement; Unregistered sale of shares32
  5. Oct 9, 20248-K Listing notice or transfer33
  6. Sep 19, 20248-K Entered a material agreement; Unregistered sale of shares34
  7. Sep 13, 20248-K Executive or director change35
  8. Aug 20, 20248-K Other events36
  9. Aug 14, 20248-K Regulation FD disclosure37
  10. Jul 31, 20248-K Other events38
  11. Jun 6, 20248-K Regulation FD disclosure39
  12. May 9, 20248-K Shareholder vote40
  13. Aug 9, 2018New chief executive Maurice Zauderer becomes CEO13

Filings

266 filings to the SEC since October 2021: 5 annual reports, 10 quarterly reports, 50 major events, 74 insider forms, 21 large holders, 4 private raises, 102 other. The latest 20:

  1. Apr 15, 202510-K EDGAR
  2. Apr 1, 2025NT 10-K EDGAR
  3. Mar 27, 202515-12G EDGAR
  4. Mar 25, 2025EFFECT EDGAR
  5. Mar 25, 2025EFFECT EDGAR
  6. Mar 25, 2025EFFECT EDGAR
  7. Mar 25, 2025EFFECT EDGAR
  8. Mar 25, 2025EFFECT EDGAR
  9. Mar 25, 2025EFFECT EDGAR
  10. Mar 25, 2025EFFECT EDGAR
  11. Mar 25, 2025EFFECT EDGAR
  12. Mar 25, 2025EFFECT EDGAR
  13. Mar 25, 2025EFFECT EDGAR
  14. Mar 25, 2025EFFECT EDGAR
  15. Mar 25, 2025EFFECT EDGAR
  16. Mar 25, 2025EFFECT EDGAR
  17. Mar 25, 2025EFFECT EDGAR
  18. Mar 25, 2025EFFECT EDGAR
  19. Mar 25, 2025POS AM EDGAR
  20. Mar 25, 2025POS AM EDGAR

The 266 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

17 open-market trades by officers, directors and large owners since October 2021: 15 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 9, 2024FRIEDBERG ALBERTDirectorBuy100$4.51$451Form 4
Aug 6, 2024FCMI Parent Co.10% ownerBuy2,753$4.92$13.5KForm 4
Aug 5, 2024FCMI Parent Co.10% ownerBuy3,653$4.60$16.8KForm 4
Aug 1, 2024FRIEDBERG ALBERTDirectorBuy11,703$4.72$55.2KForm 4
Jul 31, 2024FCMI Parent Co.10% ownerBuy200,000$6.15$1.2MForm 4
May 30, 2024FRIEDBERG ALBERTDirectorBuy861$5.20$4.5KForm 4
May 29, 2024FRIEDBERG ALBERTDirectorBuy957$4.95$4.7KForm 4
Apr 19, 2024FRIEDBERG ALBERTDirectorBuy282$4.73$1.3KForm 4
Dec 26, 2023Van Strydonck, Gerald E.DirectorSale3,149$0.72$2.3KForm 4
Dec 8, 2023Van Strydonck, Gerald E.DirectorSale1,334$0.67$894Form 4
Oct 4, 2023Zauderer MauricePresident and CEOBuy5,000$0.97$4.8KForm 4
Oct 3, 2023Zauderer MauricePresident and CEOBuy505,000$1.00$504.6KForm 4
Oct 3, 2023FRIEDBERG ALBERTDirectorBuy3,000,000$1.00$3.0MForm 4
Feb 23, 2022Van Strydonck, Gerald E.DirectorBuy20,000$1.32$26.4KForm 4
Jan 27, 2022Frieberg Jacob B.DirectorBuy90,090$1.11$100.0KForm 4
Jan 27, 2022FRIEDBERG ALBERTDirectorBuy3,603,602$1.11$4.0MForm 4
Jan 27, 2022Zauderer MauricePresident and CEOBuy1,801,801$1.11$2.0MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Sep 18, 2024Raised $200,155 in a private offering of securities Form D: $9.2 million offered in all Form D
  2. Mar 29, 2024Raised $1.8 million in a private offering of equity Form D: $3.5 million offered in all Form D
  3. Mar 28, 2024Filed a private offering of securities Form D: $1.5 million offered in all Form D
  4. Mar 28, 2024Raised $1.2 million in a private offering of equity Form D: $2.5 million offered in all Form D

SEC filer profile

How VACCINEX, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARVACCINEX, INC.1
  • CIK0001205922
  • Employer ID (EIN)16-16032023
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address1895 Mount Hope Ave, Rochester, NY 146201
  • Phone585-271-27001
  • Shares outstanding2,676,637 shares as of Apr 11, 20253
  • Public float$5.6M as of Jun 30, 20243
  • AuditorDeloitte & Touche LLP, Rochester, New York PCAOB ID 34; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceNov 12, 20021
  • Filings475 in all: 4 (143), 8-K (75), EFFECT (31), 10-Q (20), CORRESP (20), 3 (18), SC 13D/A (18), UPLOAD (17)1
    All 44 form types

    POS AM (15), S-3 (14), 4/A (11), D (10), 424B3 (8), DEF 14A (8), 10-K (7), 424B5 (7), SC 13G (6), SC 13G/A (4), REGDEX (3), S-1/A (3), S-3/A (3), 3/A (2), 424B4 (2), 8-K/A (2), ARS (2), DRSLTR (2), NT 10-K (2), PRE 14A (2), S-1 (2), S-8 (2), S-8 POS (2), SC 13D (2), 10-K/A (1), 10-Q/A (1), 15-12G (1), 25 (1), 8-A12B (1), CERT (1), CT ORDER (1), DRS (1), DRS/A (1), REGDEX/A (1), S-1MEF (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (10-K) Apr 15, 2025
    Quarterly report (10-Q) Nov 14, 2024
    Proxy statement (DEF 14A) Apr 2, 2024
    Latest 8-K (8-K) Mar 19, 2025

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.0001 per shareVCNXNONE

From the cover page of the 10-K filed Apr 15, 2025 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks VACCINEX, INC. names in Item 1A of its 10-K filed Apr 15, 2025: 50 risks under these headings, as written.3

  • Risks Related to Our Financial Position and Capital Needs
  • Risks Related to Our Business and Industry
  • Risks Related to our Dependence on Third Parties
  • Risks Related to Intellectual Property
  • Risks Related to Our Securities
  • We have incurred net losses since our inception and anticipate that we will continue to incur net losses for the foreseeable future.
  • We currently have very limited product revenue and may never achieve or maintain profitability.
  • We will require additional capital to finance our operations to continue as a going concern, which may not be available to us on acceptable terms, if at all. As a result, we may not complete the development and commercialization of our product candidates or develop new product candidates and have substantial doubt about our ability to continue as a going concern.
  • We have identified material weaknesses in our internal control over financial reporting, and if our remediation of such material weaknesses is not effective, or if we fail to develop and maintain an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable laws and regulations could be impaired.
  • The restatement of certain previously issued financial statements may affect stockholder and investor confidence or harm our reputation, and may subject us to additional risks and uncertainties, including increased cost and the increased probability of legal proceedings, regulatory inquiries, sanctions, or investigations.
  • Our ability to use net operating loss and credit carryforwards may be limited as a result of the effects of changes in tax laws and regulations.
  • We may not be able to pay debt and obligations when due.
The other 43 risks
  • We may choose not to continue to pursue our clinical trial evaluating pepinemab for the treatment of Alzheimer’s Disease and, if we do continue to pursue trials for the treatment of Alzheimer’s Disease, the development pathway is uncertain, which may make development more unpredictable or difficult than we currently expect.
  • Our product candidates are in preclinical development or the early stages of clinical development. We cannot predict if we will meet safety and efficacy endpoints in clinical trials, if our preclinical studies and clinical trials will produce positive results, or if we will receive regulatory approval to commercialize and market any of our product candidates.
  • We depend heavily on the success of our lead product candidate, pepinemab, and if we had to cease developing pepinemab, it would have material adverse effects on our business and future prospects.
  • If we experience any continued delays in clinical testing, it will delay any potential approvals of our product candidates, our costs may increase, and our business may be harmed.
  • We may not successfully identify, develop or commercialize new product candidates or new applications of our existing product candidates.
  • Our product candidates may cause undesirable side effects or have other properties that could prevent their regulatory approval, limit the commercial scope of their approved uses, or result in significant negative consequences following any marketing approval.
  • We may be required to suspend, repeat or terminate our clinical trials if they are not conducted in accordance with regulatory requirements, the results are negative or inconclusive, the trials are not well designed, or a regulator may request or require additional trials.
  • We are subject to multiple manufacturing risks, any of which could substantially increase our costs and limit supply of our product candidates.
  • The regulatory review processes of the FDA and comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. Our inability to obtain regulatory approval, in the timelines we anticipate or at all, for our product candidates would substantially harm our business.
  • Even if our product candidates receive regulatory approval, they may still face future development and regulatory difficulties such as ongoing regulatory compliance and obligations.
  • Our failure to obtain regulatory approval in international jurisdictions would prevent us from marketing our product candidates in those jurisdictions and hurt our prospects.
  • Our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success.
  • Our competitors may develop and market products or services that are less expensive, more effective, safer, otherwise regarded as preferable to, or that reach the market sooner, than our product candidates, which may diminish or eliminate the commercial success of any products or services we commercialize.
  • We may not be able to achieve continued observable effects or the benefits or synergistic effects of pepinemab in combination with other immunotherapies that we have observed in preclinical studies of pepinemab in combination with the anti-CTLA-4 antibody ipilimumab.
  • We may need to develop or obtain additional capabilities, or enter into arrangements with third parties, to commercialize any product candidates that obtain regulatory approval, and we may encounter unexpected costs or difficulties in doing so.
  • Even if we commercialize a product candidate, it or any other product candidates that we develop may become subject to unfavorable pricing regulations, third-party coverage or reimbursement practices or healthcare reform initiatives, which could harm our business.
  • Current and future legislation may increase the difficulty and cost for commercialization of our product candidates and affect the prices we or our partners may obtain.
  • If we are able to successfully commercialize any of our product candidates and if we participate in the Medicaid drug rebate program or other governmental pricing programs, failure to comply with reporting and payment obligations under these programs could result in additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
  • Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of our product candidates.
  • Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse, transparency and other healthcare laws and regulations, the violation of which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.
  • Our internal computer systems, or those used by our CROs or other contractors or consultants, may fail or suffer security breaches, which may result in penalties and liabilities under certain healthcare laws.
  • Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.
  • We depend on key personnel for our continued operations and future success and a loss of certain key personnel could significantly hinder our ability to move forward with our business plan.
  • We rely on third parties to conduct our preclinical studies and clinical trials. If these third parties, now or in the future, do not successfully carry out their contractual duties, comply with budgets and other financial obligations or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates in a timely or cost-effective manner.
  • We depend on third-party manufacturers for the manufacture of drug substance and drug product for clinical trials as well as on third parties for our supply chain. Any problems we experience with any of these third parties could delay the manufacturing of our product candidates, which could harm our results of operations.
  • We may not succeed in establishing and maintaining additional collaborations, which could adversely affect our ability to develop and commercialize product candidates.
  • Collaborations may require us to relinquish important rights to and control over the development of our product candidates or otherwise be subject to unfavorable terms.
  • If we are unable to obtain, maintain or protect intellectual property rights, both in the U.S. and throughout the world, we may not be able to compete effectively in our market or globally.
  • Changes in patent law and legal precedent concerning patents could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
  • We may become involved in lawsuits to protect or enforce our intellectual property rights, which could be expensive, time-consuming, distracting, unpredictable, and unsuccessful, and therefore could have a materially adverse impact on the success of our business and financial condition.
  • Third parties may initiate legal proceedings against us alleging that we or our employees infringe their intellectual property rights, or we may initiate legal proceedings against third parties to challenge the validity or scope of intellectual property rights controlled by third parties, the outcome of which would be uncertain, and an adverse determination could have a materially adverse effect on the success of our business and financial condition.
  • The terms of our patents may not be sufficient to effectively protect our drug candidates and business.
  • If we do not obtain additional protection under the Hatch-Waxman Amendments and similar legislation in other countries extending the terms of our patents, if issued, relating to our drug candidates, our business may be materially harmed.
  • If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could be required to pay monetary damages or could lose license rights that are important to our business.
  • Our inability to protect our confidential information and trade secrets would harm our business and competitive position.
  • Our Common Stock was delisted from trading on Nasdaq and is currently available for quotation on the OTCPK Market, which involves additional risks compared to being listed on a national securities exchange. Our ability to sell equity securities and the liquidity of the Common Stock will be adversely affected if we are unable to transfer our listing to another national securities exchange or, at minimum, a medium that offers greater liquidity than the OTCPK Market.
  • The relatively low trading volume of our common stock may limit your ability to sell your shares.
  • Our common stock is subject to the penny stock rules, which makes our common stock less liquid.
  • The Series A Preferred Stock ranks senior to the Company’s common stock with respect to rights on the distribution of assets upon liquidation, dissolution and winding up.
  • Shares of common stock issuable upon conversion of our Series A Preferred Stock will be dilutive to our existing stockholders upon conversion and adversely affect the market price of our common stock.
  • Certain of our management, including our chief executive officer, chairman of our board, and their affiliates, own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.
  • We may sell additional equity or debt securities or enter into other arrangements to fund our operations, which may result in dilution to our stockholders and impose restrictions or limitations on our business.
  • Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.

Legal proceedings

From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
    SEC EDGAROther events
  37. 37
  38. 38
    SEC EDGAROther events
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45